SCHEMBL2183292

SCHEMBL2183292

COC(=O)c1nc(Cl)c(Cl)nc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.58
KDM4E B2RXH2 7/20 0.39
ALDH1A1 P00352 6/20 0.39
L3MBTL1 Q9Y468 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
PKM P14618 2/20 0.39
KDM4C Q9H3R0 1/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 1/20 0.38
NFKB1 P19838 1/20 0.38
RAB9A P51151 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
RCE1 Q9Y256 1/20 0.36
S1PR4 O95977 1/20 0.35
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
STAT3 P40763 1/20 0.34
HIF1A Q16665 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9091123 0.91 NPSR1 (0.71) NPSR1KDM4EALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL12108293 0.85 NPSR1 (0.52) NPSR1KDM4EALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL20302593 0.85 NPSR1 (0.52) NPSR1KDM4EALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL1299960 0.84 NPSR1 (0.50) NPSR1KDM4EALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL11730515 0.83 NPSR1 (0.54) NPSR1KDM4EALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL29987712 0.83 NPSR1 (0.54) NPSR1KDM4EALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL507599 0.83 NPSR1 (0.54) NPSR1KDM4EALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL30020649 0.83 NPSR1 (0.54) NPSR1KDM4EALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL15900342 0.83 NPSR1 (0.54) NPSR1KDM4EALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL9091128 0.83 NPSR1 (0.60) NPSR1KDM4EALDH1A1L3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293729-B2 Compounds, pharmaceutical composition and methods relating thereto BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-23 US disclosed
EP-2445878-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO Boehringer Ingelheim International GmbH (DE) 2012-05-02 EP disclosed
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-07 US disclosed
WO-2010149684-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO MC2R, REN, CYP11B2 NPSR1 232/4885KDM4E 3718/4885ALDH1A1 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.